Inclusion Criteria:

- Male and female patients aged over 18 years

- Histologically proven lung adenocarcinoma

- clinical stage IIIB/IV

- ECOG performance status 0-2

- Had no prior anticancer agent, radiation or surgical therapy for lung adenocarcinoma

- At least one measurable lesion (according to RECIST)

- Provision of written informed consent

- Life expectancy of at least 12 weeks

Exclusion Criteria:

- History of malignant disease.

- Evidence of clinically active interstitial lung diseases (patients with chronic,
stable, radiographic changes who are asymptomatic need not be excluded)

- Expected life expectancy less than 2 months

- As judged by the investigator, any evidence of severe or uncontrolled systemic
disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal
disease)

- Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x
ULN if no demonstrable liver metastases (or >5 x in presence of liver metastases)

- Evidence of any other significant clinical disorder or laboratory finding that makes
it undesirable for the subject to participate in the study

- Pregnancy or breast-feeding women (women of child¬bearing potential). Women of
childbearing potential must practice acceptable methods of birth control to prevent
pregnancy.